Influenza affects 5-10% of adults and 20-30% of children each year.1 Whether it’s a typical flu season, or a worst-case pandemic, testing and screening for influenza A and B can help protect patients.
Get the speed and reliability you need to support a timely, accurate diagnosis with the cobas® Influenza A/B Assay. A multi-plex real-time PCR assay, cobas® Influenza A/B differentially detectes both influenza A and influenza B in ~20 minutes.
The fast, reliable cobas® Influenza A/B test enables healthcare professionals to support a timely, accurate diagnosis.2
The provided transfer pipette helps adding the patient sample to the assay tube.
The cobas® Liat® Analyser´s built-in barcode reader scans the barcode on the assay tube sleeve and the patients sample ID.
After inserting the assay tube, the cobas® Liat® Analyser automatically begins to run the test. About 15 minutes later, definitive results appear on the screen.
The cobas® Influenza A/B nucleic acid test for use on the cobas® Liat® System, is an automated multiplex real-time RT-PCR assay for the rapid in vitro qualitative detection and discrimination of influenza A virus and influenza B virus RNA in nasopharyngeal swab specimens from patients with signs and symptoms of respiratory infection in conjunction with clinical and epidemiological risk factors.
The test is intended for use as an aid in the differential diagnosis of influenza A and influenza B in humans and is not intended to detect influenza C.
The cobas® Liat® System is commercially available in select markets. This product is not registered as an in vitro diagnostic (IVD) in all countries; additional information may be available from your Roche sales representative.
Access package inserts through your country’s Roche Diagnostics website.